A Better Healthcare Stock To Buy: Raffles Medical Group Ltd Vs. Singapore O&G Ltd (Part 3)
- Original Post from The Motley Fool Sg

Healthcare companies are generally considered as defensive stocks since their services are needed when the economy’s good as well as bad. The defensive nature of their businesses also makes healthcare companies attractive to investors.


There are many healthcare companies in Singapore’s stock market and you might want to know which is a better investment opportunity. There’s no easy answer, but I want to directly compare the important business and valuation aspects of two healthcare services providers –Raffles Medical Group Ltd (SGX: BSL)andSingapore O&G Ltd (SGX: 1D8)– in a mini article-series.


This article is the third and last in the series and it compares the valuations of the two healthcare companies. In particular, the valuation metrics I will focus on are the price-to-book (PB) ratio, price-to-earnings (PE) ratio, and dividend yield. Myfirst article in the seriescompared the most recent quarterly earnings updates of the pair, while thesecond articlelooked at their long-term track record of growth.


The business


Raffles Medical is a leading integrated private healthcare provider in the region. In Singapore, it has a large network of clinics and medical centres, in addition to its flagship Raffles Hospital, which provides tertiary medical care. The company also has medical facilities beyond Singapore in 12 cities across China, Japan, Vietnam, and Cambodia. The medical facilities in China include two hospitals that Raffles Medical is developing in Chongqing and Shanghai; the hospitals are expected to be completed in the fourth quarter of 2018 and the second half of 2019, respectively.


Meanwhile, Singapore O&G is a specialist healthcare services provider that has a focus on women’s health. The company has four business arms: Obstetrics and Gynecology; Cancer-related; Pediatrics; and Dermatology. Singapore O&G sources all its revenue from Singapore at the moment.


The showdown


The table below shows the valuations of the two healthcare companies as of 22 October 2018:























Company PB ratio PE ratio Dividend yield
Raffles Medical 2.45 25.00 2.16%
Singapore O&G 3.56 14.77 4.97%

Source: SGX Stock Facts


Looking at the table above, I think it’s clear that Singapore O&G is the cheaper among the two due to its lower PB and PE ratios.


The Foolish conclusion


As a recap, it was Singapore O&G that had the best performance when I compared the two healthcare companies’ most recent quarterly earnings updates in my first article in the series. It was also Singapore O&G with the better report card for long-term growth, as discussed in my second article. And as we’ve just seen, Singapore O&G is again the company with the best valuation. So, Singapore O&G has emerged as the winner by coming out ahead in all three of my criteria.


But with all the above been said, investors are reminded that the information presented in the series is by no means a recommendation to take any action on Raffles Medical and Singapore O&G. Instead, the information should be viewed only as a useful starting point for further research.


$Singapore O&G(1D8.SI) $Raffles Medical(BSL.SI)

Read more
3 likes

Recommended & Related Posts

Here’s How Much You Would Have Made If You Had Invested S$1,000 in Raffles Medical Group 20 Years Ago
- Original Post from The Motley Fool Sg


Over the last five years, Raffles Medical Group Ltd (SGX: BSL) shares have tumbled 28% and now trade close to a five-year low.However, that is not to say that the healthcare giant has not been a massive winner over the longer term. Since it was listed in Singapore in 2000, the healthcare provider has grown at a breakneck pace, becoming one of Singapore’s most recognisable healthcare brands.


Looking back


I took a trip down memory lane to see how much an investor would have made if they had invested in Raffles Medical around 20 years ago.


In 2000, shares of Raffles Medical traded at a split-adjusted price of 23.5 Singapore cents per share. Today, Raffles Medical shares exchange hands for around 96.5 Singapore cents. That equates to a 310.6% gain in that time frame. For perspective, $1,000 invested at that time would now be worth S$4,106.


Doing the math, that translates to a decent annualised growth of 7.3%. On top of that, Raffles Medical has been a regular payer of dividends. Last year, Raffles Medical paid out a dividend of 2.5 Singapore cents per share. Based on an initial outlay of 23.5 Singapore cents per share in 2000, that would translate into a juicy 10.6% annual yield on the initial investment.


Not a smooth ride


However, the returns of the stock were by no means smooth. From 2000 to 2008, its shares rose by almost 100%. Unfortunately, the great financial crisis of 2008 scared off many investors who began selling down the stock, which soon returned to its 2000 level.


But Raffles Medical in 2009 was in a much better position than it was in 2000. Its 2009 revenue was three times more than it was in 2000, while its profit was more than seven times higher.


Unsurprisingly, the dip in its share price then was short-lived. Its shares soon started regaining all that it had lost in 2008 and more.


Lessons learnt


There are a few lessons that can be learnt from Raffles Medical’s twenty-year history.



  1. Never underestimate the power of long-term investing. Despite the volatility, investors who were patient enough to hold on to its shares for the whole 20 years have been well-rewarded.

  2. Do not panic during a broad market sell-off. As seen in 2008, even fundamentally sound companies suffered major sell-downs. As investors, it is easy to panic and push the sell button at the first sign of trouble. However, investors who did sell would have not enjoyed the massive gains that Raffles Medical has afforded loyal shareholders.


Today, Raffles Medical shares have again suffered a massive sell-down. It currently trades at around 30.6 times its annualised earnings. At a glance, this may not seem excessively cheap. However, there are a few things to note.


First, Raffles Medical Group earnings have been dragged down due to near-term teething losses from the opening of its first hospital in China. Second, despite the risks involved, the new China hospitals could potentially be a huge driver of profits over the longer term. Co-founder and chairman, Dr. Loo Choon Yong, is hopeful that China will contribute more than 50% of the group’s revenue in the future.


As such, its shares could see a massive boost once its China hospitals start turning profitable. If the past is anything to go by and considering the healthcare provider’s massive potential in China, I think it is likely that patient investors who pick up shares today will be well-rewarded in the next 20 years.


Want to read about another Singapore stock we love? Read about one of our stock picks that has shot up 78% in just 2 years. We reveal the amazing story behind this stock …and how you can potentially profit from it. Click here to download the free report now.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has recommended shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Raffles Medical Group Ltd’s Share Price Plunged 20% in 2019. Here’s Why.
- Original Post from The Motley Fool Sg


Raffles Medical Group Ltd (SGX: BSL) runs hospital and healthcare services in Singapore. It also has a network of clinics in five countries and thirteen cities. Furthermore, it has two hospitals (one under development) in China.


Year-to-date, Raffles Medical’s share price declined by 20% from its peak of S$1.20. Here, let’s try to understand what might have caused the decline.


The culprit


There are many reasons that cause the stock price of a company to move. Generally, stock price movement is driven either by business performance or investor sentiments.


The former is related to how a business performs in a given period, looking at metrics like growth, margins, production and others. Here, the ultimate driver is profit. The latter is driven more by investors’ overall mood, which is described by emotional pairs such as greed and fear, optimistic and pessimistic, bull and bear, etc.


In this case of Raffles Medical, I believe both factors contribute to the recent decline in its share price.


Let’s start with the some numbers.


In the first half of 2019, Raffles Medical reported that revenue was up by 6.2% year-on-year to S$255.3 million. Yet, profit for the period fell by 13.5% to S$27.9 million. The decline in profit was driven mainly by gestation losses by Raffles Hospital Chongqing.


Clearly, the decline in net profit has impacted the company’s share price. On a positive note, Raffles Medical continued to grow its top-line.


Overall, I feel it’s not all that bad.


Nevertheless, the market clearly expected more from the company. This might explain the 20% decline in the healthcare provider’s share price (which is more than the 13.5% decline in net profit for the period).


Looking ahead


Going forward, Raffles Medical needs to prove that it can ramp up the operation of its hospitals in China to improve its bottom-line. Moreover, it will also need to control its cost to improve its profitability.Failure to improve its profitability will likely put its share price in the firing line again.


Want to keep up to date with how market volatility can impact the investment landscape here in Singapore? Click here now for your FREE subscription to The Motley Fool’s investing newsletter. ‘Take Stock’ lets you know exactly what’s happening in today’s markets, and shows how you can protect your wealth in the years ahead by clicking here


More reading



The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore contributor Lawrence Nga doesn’t own shares in any companies mentioned. The Motley Fool Singapore has recommended the shares of Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Better Buy: Raffles Medical Group Ltd vs. IHH Healthcare Bhd
- Original Post from The Motley Fool Sg


Raffles Medical Group Ltd (SGX: BSL) and IHH Healthcare Bhd (SGX: Q0F) are two of the largest healthcare companies listed in Singapore. Both companies operate hospitals and medical centres around the region.


In the last five years, IHH Healthcare’s stock has declined 3.6%, while Raffles Medical’s shares have plunged 26.5%. While the pair of healthcare companies have not fared so well in the past, the future may sing a different tune, with both companies making big strides by opening new hospitals in China.


With that said, here’s a quick comparison to find out which of the two companies makes a better investment today.


Introducing the contenders


On the surface, Raffles Medical Group Ltd and IHH Healthcare Bhd have fairly similar businesses. But there are actually important differences to appreciate.


Raffles Medical Group owns a network of medical clinics and a hospital in Singapore. It also has an investment property in Holland Village that contributes rental income. The group recently expanded overseas by acquiring a network of clinics in China and also opened a joint venture hospital in Chongqing, China. A second hospital in China is expected to be opened later this year.


IHH Healthcare Bhd is a much larger company than Raffles Medical. It operates 84 hospitals around the world, including well-known brands such as Gleneagles and Parkway in Singapore. It also has a 35.69% stake in Parkway Life REIT.


The group is opening a Gleneagles in Chengdu and Shanghai over the next few quarters and acquired a 31.17% stake in Fortis Healthcare last year, expanding its footprint in India.


Growth prospects


Both Raffles and IHH have decent growth prospects.


Raffles Medical Group opened its first hospital in China late last year and will be opening a second hospital there later this year. While these two new hospitals are expected to incur gestational losses at the start, they will hopefully eventually become profitable and start being accretive to earnings.


IHH Healthcare has also laid the foundations for future growth.The group’s Gleneagles Hong Kong hospital was set up in 2017 and is still undergoing stabilisation. And as mentioned earlier, IHH is also opening two new hospitals in Chengdu and Shanghai, which are expected to be open in the fourth quarter of 2019 and the second half of 2020 respectively. On top of that, 2019 is the first year that the newly-acquired stake in Fortis will contribute to its bottom line.


However, because of IHH’s relatively larger size, it will take much more to move the needle for the company. As such, I believe Raffles’ two new hospitals in China will make a bigger impact on its bottom line than what IHH has in its pipeline.


Winner: Raffles Medical Group


Financial strength


Beyond their runway for growth, another important aspect to compare is the pair’s financial muscle and cash reserves. A larger cash reserve means that a company will not need to dip into debt markets that can increase its financing costs.


Raffles Medical does considerably better in this respect. It has a net-debt-to-equity ratio of just 0.03 times.


On the other hand, IHH Healthcare has a net-debt-to-equity ratio of 0.15 times.


Winner: Raffles Medical Group


Valuation


Lastly, from a valuation standpoint, Raffles Medical seems to come out on top again. Based on 2019 first-half results, Raffles Medical has a price-to-annualised earnings of around 31 times, while IHH shares trade at around 66 times its annualised earnings.


Raffles Medical also trades at a price-to-book ratio of 2.16 compared to IHH healthcare which trades at a price-to-book of around 2.27 (after excluding perpetuities and non-controlling interests).


On both counts, Raffles Medical Group looks to be the cheaper option.


Winner: Raffles Medical Group


The Foolish conclusion


All things considered, Raffles Medical Group seems to be the better buy for now. Not only does it have better growth prospects in terms of its size, but Raffles also has a lower net-debt-to-equity ratio and its shares trade at a discount to IHH shares.


Want to know one Singapore stock that’s set to keep growing its dividends and deliver growth? We reveal our FREE stock report for all our readers and why we think it will reward investors. Click here now to download the report now.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has recommended shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Best Healthcare Stock: Raffles Medical Group Ltd or Singapore O&G Ltd?
- Original Post from The Motley Fool Sg


Healthcare companies are generally considered “defensive” stocks since their services are needed in both the good and the bad times. Given their defensive nature and the current fears in the market about a recession, it is not surprising to see that investors are attracted to these stocks.


For those who are seeking investment ideas in this sector, you might want to know which companies you should invest in. In this article, I’ll compare two companies that have exposure to this sector, namely Raffles Medical Group Ltd (SGX: BSL) and Singapore O&G Ltd. (SGX: 1D8).


What I want to find out here is which of the two is the better deal now for investors.


Valuation


To find out which is cheaper, I’ll compare the valuation metrics of both companies. The three valuation metrics I will focus on are the price-to-book (PB) ratio, price-to-earnings (PE) ratio, and dividend yield.


To begin with, Raffles Medical and Singapore O&G have PB ratios of 2.2 and 3.8, respectively. The low PB ratio for Raffles Medical suggests that it has a lower valuation.


Next, Raffles Medical and Singapore O&G have PE ratios of 26.1 and 22.8, respectively. Here, Singapore O&G appears to have a lower valuation.


Last but not least, the dividend yields for Raffles Medical and Singapore O&G are 2.6% and 4.2%, respectively. The higher a stock’s yield, the lower its valuation. Thus, we can see that Singapore O&G has the lower valuation in terms of the dividend yield.


From the above, we can argue that Singapore O&G is probably the cheaper stock among the two due to its low PE ratio and high dividend yield.


Conclusion


For investors, the main takeaway is that Singapore O&G is probably the better deal now due to its low valuation. Yet, investors should also consider the prospects of both companies before investing in their stocks.


Want to start investing but worried about costly mistakes? Our “Heartland Investor” e-book reveals the 1 thing you should NEVER do in the stock market…including ways to handle market crashes. Download the e-book for FREE right here


More reading



The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore contributor Lawrence Nga doesn’t own shares in any companies mentioned. The Motley Fool Singapore has recommended the shares of Raffles Medical Holdings Ltd and Singapore O&G Ltd.



$Raffles Medical(BSL.SI)

Read more
Stocks to Watch: Singapore Airlines Ltd and Raffles Medical Group Ltd
- Original Post from The Motley Fool Sg


Earnings season is upon us again. Singapore Airlines Ltd (SGX: C6L) and Raffles Medical Group Ltd (SGX: BSL) are two companies that will be releasing their results this week. Here’s what to look out for.


First steps in China…


Raffles Medical Group opened its first hospital in China — Raffles Hospital Chongqing — earlier this year. In the first quarter of 2019, the group’s revenue grew 6.7% but profit attributable to owners declined 13.7%.


The loss was expected due to gestational loss of the new China hospital. Executive chairman, Dr Loo remained optimistic about the group’s expansion into China, saying,


“The opening of RafflesHospital Chongqing marks the beginning of a bold new venture into the Chinese healthcare market of 1.4 billion people, and it will provide the Group with unlimited opportunities to expand its services.”


Besides Raffles Hospital Chongqing, another hospital in Shanghai is currently under construction and is expected to open in 2020. Preparatory works for commissioning and operational phase has already begun in Singapore.


The group, which also operates Raffles Hospital in Singapore, has taken up loans to fund its investments. However, its core business is still generating a healthy cash flow. In the first quarter of 2019, cash flow from operations was S$21.7 million, compared to its net debt position of S$14.2 million. The cash generated will provide the group with the financial muscle needed during its first steps into China.


Raffles Medical Group released its second-quarter results earlier today. Investors should look out for updates on losses incurred in China and whether the construction and opening of Shanghai Hospital are within schedule. Raffles Specialist Centre in Singapore was also officially opened on 12 March 2019. This should provide another revenue stream to the group.


Climbing new heights


Singapore Airlines was in the spotlight earlier this year when it issued bonds to raise funds to increase its fleet.The group has now spent over S$11 billion over the last two years on aircraft, spares and engines as it embarks on a major expansion phase.


This is part of a three-year transformation program, whereby Singapore’s flagship carrier is working to pivot to keep relevant in the highly competitive airline industry. One of its business initiatives is to upgrade Silkair’s fleet to eventually merge it with Singapore Airlines.The group is also pushing to transform Singapore Airlines into one of the world’s leading digital airlines.


However, investors need to keep an eye on the group’s financial position. The parent company of Scoot is now in a net debt position of more than S$3 billion, from a net debt position of under S$1 billion at the start of FY2018.While the group continues to generate healthy operating cash flows, its high net debt position has weakened its financial standing.


Investors will also need to keep an eye on the fuel prices, which can materially impact the group’s operating costs.Singapore Airlines will be releasing its results on Wednesday, 31 July 2019.


Want to better understand how to benefit from the investing landscape here in Singapore? Click here now for your FREE subscription to The Motley Fool’s investing newsletter. ‘Take Stock’ lets you know exactly what’s happening in today’s markets, and shows how you can GROW your wealth in the years ahead here


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore recommends shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares of Raffles Medical Group Ltd.


$SIA(C6L.SI) $Raffles Medical(BSL.SI)

Read more
About Contact Privacy Terms Widgets Store

There are more for you ...

View more and participate in our discussion now. It's FREE.

Creating an account means you’re okay with InvestingNote's Terms and Conditions